▲ KakaoHealthcare, Pangyo Headquarters
– Approximately 50 officials and entrepreneurs from global medical product regulatory authorities and global companies visit KakaoHealthcare, including the KFDA and the FDA, the co-hosts of AIRIS 2024(AI Regulatory & International Symposium: Use of AI in Medical Product Development)
– KakaoHealthcare demonstrates its AI-based, mobile glucose management service, PASTA, and introduce RWE, RWD-based clinical and new drug development projects with examples of collaborations
– KakaoHealthcare shares experiences of developing digital medical devices using AI and global projects based on RWE and RWD
[February 26, 2024] KakaoHealthcare, led by CEO Hwang Hee, announced the visit of approximately 50 officials and entrepreneurs from global medical product regulatory authorities and global companies, including the KFDA and the FDA, the co-hosts of AIRIS 2024(AI Regulatory & International Symposium: Use of AI in Medical Product Development) to KakaoHealthcare Pangyo headquarters.
Leading figures in the global healthcare landscape, including Sameer Pujari, AI Lead at the World Health Organization (WHO), David Reese, CTO and Vice President of global pharmaceutical company, Amgen, and many other representatives from major global regulatory agencies such as the U.S. Food and Drug Administration(FDA), and global medical AI entrepreneurs visited KakaoHealthcare. On this day, they witnessed firsthand the company’s innovative use of big data and AI in the development of digital healthcare products such as digital medical devices and new drugs, and shared relative insights and experiences.
CEO Hwang Hee demonstrated the key functions and features of KakaoHealthcare’s AI-based, mobile glucose management service, PASTA, which was launched on February 1st. The CEO additionally introduced KakaoHealthcare’s ‘Medical Big Data Analysis Solution,’ RWE(Real-World Evidence) and RWD(Real-World Data)-based research collaboration model through the ‘Multi-Institutional Research Collaboration Network (R-Alliance),’ and RWE-based precision beauty solution development cases carried out with global beauty company L’Oréal.
This visit to KakaoHealthcare was planned to take place before AIRIS 2024, allowing officials from regulatory bodies, including those from South Korea and the United States, to discuss policy directions and seek various support measures for AI-based innovative medical products from major Korean companies. AIRIS 2024 follows the signing of a memorandum of understanding last year between South Korea and the United States for mutual cooperation in the field of “AI Utilization for Medical Product Development,” and the event will be held at The Shilla Hotel Seoul in Jung-gu, Seoul, from February 26th to 29th.
CEO Hwang Hee expressed, “we are currently developing various smart healthcare products utilizing AI and conducting research projects based on RWE, RWD.” He added, “we will continue to play a leading role in the healthcare industry by integrating AI into software medical devices and collaborating with global companies.” (End)
